XJ02862-S2

HY-149971	
3023355-55-4	HŅ
C ₂₇ H ₃₁ N ₃ O ₃	· ·
445.55	N
FXR	0
Metabolic Enzyme/Protease	0₹ ^N ≠0
Please store the product under the recommended conditions in the Certificate of Analysis.	
	3023355-55-4 C ₂₇ H ₃₁ N ₃ O ₃ 445.55 FXR Metabolic Enzyme/Protease Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIV	
Description	XJ02862-S2 shows potent FXR agonistic activity. XJ02862-S2 is a promising lead compound for the research of NAFLD ^[1] .
In Vivo	XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tong Qin, et al. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease. Eur J Med Chem. 2023 Apr 5;252:115307.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet